13F Pro13F Pro

Caligan Partners LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1727492
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.2%$2.1B
  • Other0.8%$15.7M

AUM History

13fpro.ai/research/fund/caligan-partners-lp-1727492

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/caligan-partners-lp-1727492

Caligan Partners LP 13F holdings — Q2 2026

$2.1B portfolio (+41.5% QoQ) · 28 holdings · Q2 2026 13F · top 10 are 83% of the stock portfolio

Includes $53.0M of put/call options ($0 puts, $53.0M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $2.1B. Weights use the stock portfolio.

All holdings — Caligan Partners LP (Q2 2026)

28 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
RVMD$RVMDCALLRevolution Medicines, Inc.$47.2M+10%
IMCR$IMCRImmunocore Holdings plcadr$43.9MNew
VRDN$VRDNViridian Therapeutics, Inc.\DE$40.3MNew
VOR$VORVor Biopharma Inc.$35.4M—
SABS$SABSSAB Biotherapeutics, Inc.$31.1M—
IVA$IVAInventiva S.A.adr$30.9M+64%
AURA$AURAAura Biosciences, Inc.$30.5M+1770%
TYRA$TYRATyra Biosciences, Inc.$25.8M-37%
IRD$IRDOpus Genetics, Inc.$25.0M+0.0%
ANIK$ANIKAnika Therapeutics, Inc.$21.0M—
SGMT$SGMTSagimet Biosciences Inc.$19.3MNew
ARTV$ARTVArtiva Biotherapeutics, Inc.$16.8MNew
— FAETH THERAPEUTICS INC - COM NEW$15.7M+400%
MBX$MBXMBX Biosciences, Inc.$11.0M-76%
VRCA$VRCAVerrica Pharmaceuticals Inc.$5.7M—

What changed in Q2 2026

Against the previous quarter's 13F: 5 new, 11 added to, 3 trimmed, 5 sold out. Share-count changes; largest moves by dollar size first.

New positions (5)

  • IMCR$IMCRImmunocore Holdings plc$43.9M

    first bought this quarter

  • VRDN$VRDNViridian Therapeutics, Inc.\DE$40.3M

    first bought this quarter

  • SGMT$SGMTSagimet Biosciences Inc.$19.3M

    first bought this quarter

  • ARTV$ARTVArtiva Biotherapeutics, Inc.$16.8M

    first bought this quarter

  • CLRB$CLRBCellectar Biosciences, Inc.$1.3M

    first bought this quarter

Added to (11)

  • RVMD$RVMDRevolution Medicines, Inc.+19%

    now $367.4M · held 4+ qtrs, 3 adds in a row

  • AURA$AURAAura Biosciences, Inc.+1770%

    now $30.5M · held 2 qtrs, 2 adds in a row

  • AVTX$AVTXAvalo Therapeutics, Inc.+94%

    now $58.5M · held 4+ qtrs, 3 adds in a row

  • ABVX$ABVXAbivax S.A.+7%

    now $207.6M · held 4+ qtrs

  • FAETH THERAPEUTICS INC - COM NEW+400%

    now $15.7M

  • IVA$IVAInventiva S.A.+64%

    now $30.9M · held 3 qtrs, 3 adds in a row

+5 more in the Excel export

Trimmed (3)

  • MBX$MBXMBX Biosciences, Inc.-76%

    now $11.0M · held 2 qtrs

  • XENE$XENEXenon Pharmaceuticals Inc.-36%

    now $53.7M · held 4+ qtrs

  • TYRA$TYRATyra Biosciences, Inc.-37%

    now $25.8M · held 4+ qtrs

Sold out (5)

  • MLYS$MLYSMineralys Therapeutics, Inc.was $75.1M

    held 8+ qtrs

  • CGON$CGONCALLCG Oncology, Inc.was $60.9M
  • SYRE$SYRESpyre Therapeutics, Inc.was $44.3M

    held 1 qtr

  • MAZE$MAZEMaze Therapeutics, Inc.was $18.4M

    held 2 qtrs

  • XLO$XLOXilio Therapeutics, Inc.was $943K

    held 1 qtr

Firm AUM (Form ADV): $1.3B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Caligan Partners LP has filed, 14 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Caligan Partners?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Caligan Partners's top 20 holdings: 64/100 (our AI quality score, weighted by position size; 8 of the 20 are scored)

Top 10 since filing

-23.5%

Value-weighted move of the 10 largest stock positions

Turnover

13%

Last quarter

Top 10 weight

83%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

74%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q3 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Caligan Partners LP disclosed 28 positions worth $2.1B in its Form 13F-HR for Q2 2026 — $2.1B in common stock plus $53.0M of put/call option positions (reported at underlying notional value, not premium at risk), led by $LQDA (Liquidia Corp) at 31.2% of the equity portfolio, followed by $RVMD and $ABVX. During the quarter the fund opened 5 new positions and exited 5 — including a new stake in $IMCR and a full exit from $MLYS. The portfolio is most concentrated in Healthcare (99.2% of disclosed assets). All figures are sourced directly from Caligan Partners LP’s Form 13F-HR filing with the SEC under CIK 1727492.

Funds like this

managers whose biggest positions overlap Caligan Partners's
FARALLON CAPITAL MANAGEMENT LLC$21.68B 13F book · 6 shared top holdingsRVMDEXELLQDATNGXParadigm Biocapital Advisors LP$5.34B 13F book · 8 shared top holdingsRVMDTNGXPCVXVRDNTCG Crossover Management, LLC$4.16B 13F book · 9 shared top holdingsABVXTNGXVORRVMDBVF INC/IL$3.91B 13F book · 5 shared top holdingsRVMDTYRAIMCRAVTXLogos Global Management LP$2.32B 13F book · 7 shared top holdingsABVXRVMDTNGXXENEFirst Turn Management, LLC$934.72M 13F book · 5 shared top holdingsRVMDABVXPCVXXENE

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Caligan Partners LP

13F Pro is an AI hedge fund tracker and stock research platform. For Caligan Partners LP (SEC CIK: 1727492), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Caligan Partners LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.